Report from Europe: Software bugs delay start of Munich proton therapy center Feb. 5, 2008 By John Brosky
Taligen Gets $65M Series B for Complement Programs Feb. 4, 2008 By Trista Morrison Taligen Therapeutics Inc. closed a tranched Series B financing round that eventually could bring the company as much as $65 million. (BioWorld Today)Read More
RSS